The purpose of this study is to determine the optimal dose of CHF 5259 (glycopyrrolate
bromide) on top of Foster which provides the optimal additive bronchodilator effect to
asthmatic patients whose symptoms are uncontrolled with medium dose of inhaled
corticosteroids plus long acting beta2 agonists.